Trials / Completed
CompletedNCT06085482
A Phase I Study of LY3502970 in Healthy Participants
A Single-Group, Open-Label, Single-Period, Phase 1 Study to Determine the Absolute Bioavailability of LY3502970 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3502970 | Administered orally |
| DRUG | [14C]-LY3502970 | Administered IV |
Timeline
- Start date
- 2023-10-19
- Primary completion
- 2024-01-05
- Completion
- 2024-01-05
- First posted
- 2023-10-17
- Last updated
- 2024-03-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06085482. Inclusion in this directory is not an endorsement.